Pro-apoptotic and anti-proliferative effects of mitofusin-2 via PI3K/Akt signaling in breast cancer cells

Oncology Letters

Volumn 10, Issue 6, 2015, Pages 3816-3822

  Ma, Li ^a   Chang, Yuan ^a   Yu, Long ^a   He, Wenbo ^a   Liu, Yueping ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Mitofusin 2; PI3K Akt; Proliferation

Indexed keywords

CYCLIN A; CYCLINE; MITOFUSIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; BRDU ASSAY; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MTT ASSAY; OPEN READING FRAME; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; UPREGULATION; WESTERN BLOTTING;

EID: 84944722414     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3748     Document Type: Article

References (26)

1. Chen G, Liu N, Zhou A, Tang C, Ma D and Tang J: The role of hypertension-related gene in aortic vascular smooth muscle cells from mice and rats. Chin Med J (Engl) 114: 833-836, 2001.
2. Guo X, Chen KH, Guo Y, et al: Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ Res 101: 1113-1122, 2007.
3. Karbowski M, Lee YJ, Gaume B, Jeong SY, Frank S, Nechushtan A, Santel A, Fuller M, Smith CL and Youle RJ: Spatial and temporal association of Bax with mitochondrial fission sites, Drp1 and Mfn2 during apoptosis. J Cell Biol 159: 931-938, 2002.
4. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP and Tang J: Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 6: 872-883, 2004.
5. Wang W, Lu J, Zhu F, Wei J, Jia C, Zhang Y, Zhou L, Xie H and Zheng S: Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med Oncol 29: 70-76, 2012.
6. Jin B, Fu G, Pan H, Cheng X, Zhou L, Lv J, Chen G and Zheng S: Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol 28 (Suppl 1): S373-S380, 2011.
7. Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, Zhang Q and Yu JR: Anti-tumor effects of mfn2 in gastric cancer. Int J Mol Sci 14: 13005-13021, 2013.
8. MacGregor JI and Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196, 1998.
9. Sommer S and Fuqua SA: Estrogen receptor and breast cancer. Semin Cancer Biol 11: 339-352, 2001.
10. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M and Gustafsson JA: Mechanisms of estrogen action. Physiol Rev 81: 1535-1565, 2001.
11. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR and Hanby AM: Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 5: 174-181, 2004.
12. Ma L, Liu Y, Geng C, Qi X and Jiang J: Estrogen receptor β inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2. Int J Oncol 42: 1993-2000, 2013.
13. Zhang D, Ma C, Li S, Ran Y, Chen J, Lu P, Shi S and Zhu D: Effect of Mitofusin 2 on smooth muscle cells proliferation in hypoxic pulmonary hypertension. Microvasc Res 84: 286-296, 2012.
14. Fabregat I, Roncero C and Fernandez M: Survival and apoptosis: A dysregulated balance in liver cancer. Liver Int 27: 155-162, 2007.
15. Guicciardi ME and Gores GJ: Apoptosis: A mechanism of acute and chronic liver injury. Gut 54: 1024-1033, 2005.
16. Braathen GJ, Sand JC, Lobato A, Høyer H and Russell MB: Mfn2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families. BMC Med Genet 11: 48, 2010.
17. Bagchi A and Mills AA: The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551-2556, 2008.
18. de Brito OM and Scorrano L: Mitofusin 2: A mitochondria-shaping protein with signaling roles beyond fusion. Antioxid Redox Signal 10: 621-633, 2008.
19. Westermann B: Molecular machinery of mitochondrial fusion and fission. J Biol Chem 283: 13501-13505, 2008.
20. Hirai K, Hayashi T, Chan PH, Zeng J, Yang GY, Basus VJ, James TL and Litt L: PI3K inhibition in neonatal rat brain slices during and after hypoxia reduces phospho-Akt and increases cytosolic cytochrome c and apoptosis. Brain Res Mol Brain Res 124: 51-61, 2004.
21. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and Piccart-Gebhart MJ: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 39: 935-946, 2013.
22. Yi YW, Hong W, Kang HJ, Kim HJ, Zhao W, Wang A, Seong YS and Bae I: Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med 17: 648-656, 2013.
23. Pande S, Browne G, Padmanabhan S, Zaidi SK, Lian JB, van Wijnen AJ, Stein JL and Stein GS: Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol 228: 1784-1792, 2013.
24. Calleros L, Sánchez-Hernández I, Baquero P, Toro MJ and Chiloeches A: Oncogenic Ras, but not (V600E) B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells. Carcinogenesis 30: 1670-1677, 2009.
25. De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signaling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16 (Suppl 2): S17-S27, 2012.
26. Tsubaki M, Satou T, Itoh T, Imano M, Ogaki M, Yanae M and Nishida S: Reduction of metastasis, cell invasion and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol 259: 402-410, 2012.